KSC Healthcare Biotechnology 011000.KS

GeneOne Life Science, Inc.

$ 694.00 -17.67 %

GeneOne Life Science, Inc., a biopharmaceutical firm headquartered in Seoul, South Korea, was founded in 1976. The company focuses on the innovation and manufacturing of gene-based biomedical products. Its developmental pipeline features several candidates: GLS-1027 is in Phase I for nephropathy and inflammatory conditions, and also in Phase II trials for COVID-19. Similarly, GLS-1200 is being tested in Phase II for both Rhinosinusitis and COVID-19. Other compounds under development include GLS-3000 and GLS-5310 for SARS-CoV-2, GLS-5100 targeting VZV-Shingles, and GLS-5140 for SFTS. The company is also advancing GLS-5300 in Phase II for MERS, GLS-5700 in Phase I for Zika, and GLS-6150 in Phase I for hepatitis C, alongside GLS-6100 which is in a pre-clinical stage for hepatitis C. Additionally, through its subsidiary VGXI, Inc., GeneOne Life Science offers contract manufacturing services for nucleic acid-based products, specifically DNA plasmids and mRNA, under cGMP standards. The company adopted its current name in April 2014, having previously been known as VGX International Inc.

CEO: Young-Keun Park - https://www.genels.com

Summary 30-Y Financials Dividend Analyst Key metrics Ownership / Senat
Price objectif

-

Recommandation

-

DCF

$ -16 439.38

Loading data...

011000.KS vs S&P500

Loading data...

No data available.

Quick ratio

0.21

indicates that the company may have difficulty covering its short-term debts with its readily available assets.

P/E ratio

-1.02

may indicate that the company is undervalued or has poor growth prospects.

EPS

-678.50

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

-76.96 %

indicates low profitability, suggesting that the company is not using equity efficiently to generate profits.

ROIC

-40.56 %

does not generate enough return to cover its financing costs, which indicates value destruction and may pose long-term profitability issues.

WACC

7.19

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.67

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

-183.25

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

0.00 %

the dividend payout ratio is the measure of dividends paid out to shareholders relative to the company's net income.

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
2 indicates worrying financial health
Altman score
-4.07 indicates a high risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
0.10 indicates liquidity risk, as the company may not have enough cash to meet its immediate obligations
Debt Ratio
0.26 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.